← All trials
NCT06592924
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 15, 2025
- Primary completion
- Mar 14, 2031
- Completion date
- Apr 15, 2031
- First posted
- Sep 19, 2024
- Last posted
- Oct 21, 2024
- Enrollment
- 830
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Canadian Cancer Trials GroupLead sponsor
- ECOG-ACRIN Cancer Research GroupCollaborator
- SWOG Cancer Research NetworkCollaborator
- NRG OncologyCollaborator
- National Cancer Institute (NCI)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.